Pay in 4 interest-free payments of $5.82 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Triple-hormone-receptor agonist Retatrutide for obesity: Phase 2 trial (48-week study, up to 24% weight loss) American Diabetes Association (2023) ADA Press Release: Novel agent Retatrutide results in substantial weight reduction (83rd Scientific Sessions, Phase 2 data) ADA Meeting News (2023) Phase 2 trial results: benefits of Retatrutide in obesity, type 2 diabetes, NASH (83rd ADA Scientific Sessions coverage) ClinicalTrials.gov Study of Retatrutide (LY3437943) in adults with obesity (NCT04881760
Potential Side Effects: Mild discomfort at injection site, rare gastrointestinal upset for oral forms
Injection site reactions: Pain, redness, or swelling may occur at the site of injection
50MG/ML concentration with 1,000MG total content for advanced laboratory research workflows requiring clear concentration labeling
US$ 29.24
US$ 23.16
US$ 24.83
US$ 29.32
US$ 29.35
US$ 28.50
US$ 25.53
